10/19/2016 - AMCP submits comments to FDA on BsUFA II reauthorization, citing a need for robust biosimilars education, expeditious and harmonious guidance documents, and post-market surveillance.
10/19/2016 - AMCP submits comments to FDA on BsUFA II reauthorization, citing a need for robust biosimilars education, expeditious and harmonious guidance documents, and post-market surveillance.